Journal of Viral Hepatitis

Article	Citations
Issue Information	39
Age, ethnicity and proximity to clinic determine retention in care of chronic hepatitis B patients	36
Response to letter to editor: Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B	31
	28
Issue Information	26
Correlates of chronic hepatitis B virus infection in the general adult population of China: Systematic review and meta‐analysis	23
Individual Heterogeneity and Trends in Hepatitis C Infection Risk Among People Who Inject Drugs: A Longitudinal Analysis	22
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort	20
Analytical validation of hepatitis B core‐related antigen (HBcrAg) using dried blood spots (DBS)	20
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B	19
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England	17
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy	17
Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046‐miR‐1299‐RTKN2 ceRNA pathway	17
Retraction	16
Issue Information	16
Interaction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis	16
Issue Information	15
	15
	15
Reduction in hepatitis C‐related hospitalizations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences	15
Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination	15
Cover image	14
Follow‐up evaluation of patients with liver test abnormalities detected during SARS‐CoV2 infection	14
Issue Information	14
Issue Information	14

Quantitative HBsAg an unreliable marker for diagnosis and disease progression in genotype F chronic HBeAg‐negative infections	14
Sequence characterization of extracellular HBV RNA in patient plasma	14
Patient‐reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care in homeless shelters	13
Cover Image	13
Kinetics of serum O‐glycosylated M‐hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients	13
	13
A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype	13
Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents	12
Consider more about risk scores for predicting hepatocellular carcinoma in patients with chronic hepatitis B	12
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwid	12
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C	12
Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non‐cirrhotic HBeAg‐positive chronic hepatitis B	11
Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B	11
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib	11
‘There's too much power in this number. It's freaking the whole response out’: The views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia	11
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study	11
240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C	11
Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis	10
	10
	10
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co‐infection and risk of drug‐induced liver injury across two large HBV cohorts in the United	10
Different mutation rates in the basal core promoter and precore regions between hepatitis B virus subgenotype F1b clusters	10
Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy	10
Issue Information	10
Poor linkage to care may compromise the Brazilian plan for hepatitis C elimination	10
Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues	9
	9
Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)	9
Death certificates compared to SEER‐Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection	9
Sustained and cumulative impact of an electronic medical record‐based alert on a hepatitis C birth cohort screening programme	9
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China	9
Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data	8
Australian Community Pharmacists' Preparedness to Offer and Discuss Hepatitis C Testing and Treatment With Pharmacy Clients: A Representative Cross‐Sectional Survey	8
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine	8
Long‐Term Effects of Direct‐Acting Antivirals on Hepatitis C: Trends in Liver Disease–Related Hospitalisations in Italy	8
	8
Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study	8
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection	8
Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease	8
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	8
Optimization of the Use of APRI and FIB‐4 for Ruling Out Liver Cirrhosis in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase	8
Severe Liver‐Related Outcomes in Patients With Hepatitis Delta: Results From a Multi‐Ethnic Multicenter Long‐Term Follow‐Up Study	8
Hepatitis C treatment in a co‐located mental health and alcohol and drug service using a nurse‐led model of care	8
A novel multi‐epitope peptide vaccine candidate targeting hepatitis E virus: An in silico approach	7
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities	7
Hepatitis B virus–induced hepatocarcinogenesis: A virological and oncological perspective	7
Global prevalence of occult hepatitis B: A systematic review and meta‐analysis	7
Reply to: ‘Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus‐related decompensated cirrhosis’	7
Issue Information	7
Prevalence, clinical and virological characteristics and short‐term prognosis of hepatitis delta infection among patients with HIV/HBV in Nouakchott, Mauritania	7

Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study	7
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	7
	7
Classification and survival prediction in early‐stage cirrhosis by gene expression profiling	7
Large‐scale screening is not useful for identifying individuals with hepatitis B or C virus infection: A prospective Swiss study	7
The cost‐effectiveness of case‐finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK	7
The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study	7
Cost‐effectiveness analysis of an active search to retrieve HCV patients lost to follow‐up (RELINK‐C strategy) and the impact of COVID‐19	7
Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working‐age adults in Madrid (Spain)	7
Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review	7
Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis	6
The impact of the first, second and third waves of covid‐19 on hepatitis B and C testing in Ontario, Canada	6
Closing the hepatitis C treatment gap: United States strategies to improve retention in care	6
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals	6
Genetic substructure and host‐specific natural selection trend across vaccine‐candidate ORF‐2 capsid protein of hepatitis‐E virus	6
Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up	6
Global elimination of HBV: Is it really achievable?	6
Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir	6
Immunogenicity of a Birth Dose of Hepatitis B Vaccine in Kinshasa, Democratic Republic of Congo: A Randomised, Controlled Trial	6
Self‐reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013–2017: A nationwide population‐based study	6
Internet‐guided HCV‐RNA testing: A promising tool to achieve hepatitis C micro‐elimination among men who have sex with men	6
High prevalence of hepatitis B virus among MSM living with HIV in India	6
Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV‐infected people on opioid agonist therapy	6
Clinical Prevalence of Hepatitis D Virus Among Hepatitis B Patients in Sulaymaniyah Governorate, Northern Iraq	6
Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America	6
Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase	6
Evaluation of Knowledge, Attitudes and Practices for Hepatitis B Virus Infection Among Primary Healthcare Physicians in Georgia	6
The benefits of gene therapy in people with haemophilia	6
Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: A nationwide population study, 1998–2020	6
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination	6
Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis	6
Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C	6
Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B	6
	6
Issue Information	6
Mean HBsAg decline at week 24 of PEG‐IFN‐based treatment predicts subsequent rate of HBsAg clearance — suggesting a valuable endpoint for early development HBV trials	5
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply	5
Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab	5
Migrants and hepatitis: A tale of two worlds	5
Letter in response: Psychiatrists can treat hepatitis C	5
	5
Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community—A summary scoping review	5
Effectiveness of direct‐acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real‐world cohort (REACH‐C)	5
Single‐Cell Transcriptome Identifies a Proinflammatory B‐Cell Subset in Hepatitis B Virus Associated Acute‐on‐Chronic Liver Failure	5
Bocavirus Infection as a Potential Trigger for Hepatic Injury in Children	5
Psychiatrists can treat hepatitis C	5
Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals	5
	5
Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia	5
Improvement of chronic HCV infection‐related depression, anxiety, and neurocognitive performance in persons achieving SVR‐12: A real‐world cohort study	5
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study	5
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatiti	5
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD	5
Prevalence of hepatitis E infection among adults with concurrent chronic liver disease	5
Issue Information	5
Testing to sustain hepatitis C elimination targets in people who inject drugs: A network‐based model	5
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study	4
Monkeypox outbreak as an opportunity to identify new cases of HCV infection in limited resource settings	4
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B	4
Issue Information	4
Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful	4
Research progress on detection methods for hepatitis B virus covalently closed circular DNA	4
More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study	4
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts	4
HBV pgRNA profiles in Chinese HIV/HBV coinfected patients under pre‐ and posttreatment: a multicentre observational cohort study	4
	4
Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment	4
Issue Information	4
Which patients should be considered for gene therapy	4
Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications	4
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city	4
Issue Information	4
Comment on ‘Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus‐related decompensated cirrhosis’	4
Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment	4
Abnormal liver function tests and coronavirus disease 2019: A close relationship	4
Temporal and geographic spreading of hepatitis B virus genotype A (HBV‐A) in Brazil and the Americas	4
Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma	4
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis	4
Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B‐coinfected adults in care in the United States	4
Direct‐acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment	4

Issue Information	4
Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life	4
Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD	4
Issue Information	4
Hepatitis after gene therapy, what are the possible causes?	4
Prevalence of hepatitis C among pregnant women in an Appalachian population	4
Targeted antiviral treatment of hepatitis B virus in culturally and linguistically diverse populations to achieve elimination targets in Australia	4
	4
Knowledge, perception and expectation of management of hepatitis B infection among pregnant hepatitis B carriers in Hong Kong	4
	4
Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study	4
Withdrawal: CircKIAA1429 accelerates hepatocellular carcinoma advancement by miR‐199b‐5p/OTX1 pathway, by Bin Lu, Min Cheng, Tao Wang	4
Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures	4
Epidemiology estimates of hepatitis D in individuals co‐infected with human immunodeficiency virus and hepatitis B virus, 2002–2018: A systematic review and meta‐analysis	4
Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The REACH‐C cohort	4
Uptake of interferon‐free DAA therapy among HCV‐infected decompensated cirrhosis patients and evidence for decreased mortality	4
Context‐dependent accuracy of the cobas plasma separation card for HCV RNA viral load measurement	4
Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies	4
	4
	4
Issue Information	4
Issue Information	4
Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs	3
Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment	3
Misuse of the Lower Limit of Detection in HBV DNA Testing and Anti‐HBe Positive Status Will Significantly Impact the Diagnosis of Occult HBV Infection	3
Treatment decisions based on HBV DNA	3
Perspectives of People Living With Chronic Hepatitis D: Impact of Disease and Unmet Needs Along the Care Cascade	3
Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus	3
Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment	3
MiR‐155 regulates M2 polarization of hepatitis B virus‐infected tumour‐associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma	3
Issue Information	3
	3
Effects of on‐treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection	3
Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection	3
Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?	3
Sex‐related difference analyses of efficacy and safety in clinical trials of direct‐acting antivirals to treat chronic HCV genotype 1 and 3 infections	3
Integration and the risk of liver cancer—Is there a real risk?	3
The impact of direct‐acting antivirals on hepatitis C viraemia among people who inject drugs in England; real‐world data 2011–2018	3
The Disease and Economic Burden of HBV and HCV in Ethiopia	3
TRPM2 regulates autophagy to participate in hepatitis B virus replication	3
Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry	3
DAA‐PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy	3
Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone	3
Infectivity of Hepatitis B Virus Surface Antigen‐Positive Plasma With Undetectable HBV‐DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?	3
Reversibility of acute‐on‐chronic liver failure syndrome in hepatitis B virus‐infected patients with and without prior decompensation	3
Limited Value of HBV‐RNA for Relapse Prediction After Nucleos(t)ide Analogue Withdrawal in HBeAg‐negative Hepatitis B Patients	3
Delta hepatitis epidemiology and the global burden of disease	3
Randomized clinical trial: Direct‐acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly c	3
Association of HBeAg decline rate from mid‐pregnancy to delivery with HBeAg seroconversion after delivery in hepatitis B virus‐infected mothers	3
Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community	3
Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis	3
Evolution and Impact of Hepatitis A Epidemiology in Europe—Systematic Literature Review of the Last 20 Years	3
Minimising Risk in CHB Management: A Zero‐Risk Approach	3
Evaluating the prevalence of Hepatitis E virus infection in a large cohort of European blood donors, 2015–2018	3
Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?	3
Lower Serum Albumin Level: A Prospective Risk Predictor of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection	3
Incidence of hepatitis C virus infection in the prison setting: The SToP‐C study	3
	3
Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study	3
Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States	3
The elimination of hepatitis D as a public health problem: Needs and challenges	3
Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days	3
	3
Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection:	2
The complex, confusing and poorly understood immune responses to AAV‐mediated gene transfer in haemophilia—Is more or less immunosuppression required?	2
	2
Issue Information	2
Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale	2
A Network Map of Intracellular Alpha‐Fetoprotein Signalling in Hepatocellular Carcinoma	2
	2
The 5‐year cumulative incidence of HCC development and treatment regimen in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment	2
Issue Information	2
The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review	2
HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic	2
Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection	2
Low incidence and prevalence of hepatitis C in two cohorts of HIV pre‐exposure prophylaxis adherence interventions in men who have sex with men in Southern California	2
Response to Robins et al	2
A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety‐net hospital	2
Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study	2
	2
Prevalence of hepatitis C in sexual assault survivors presenting to a SANE clinic: A descriptive analysis	2
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phas	2
Viral hepatitis in pregnancy	2
HIV and HCV testing at clinical encounters among people who inject drugs, 2013–2018—Opportunities for increased testing and prevention	2
Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review	2
Willingness to participate in research among black patients with liver disease: A national cross‐sectional study	2
Issue Information	2
Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study	2
The impact of hepatitis B and C positive serologies on the outcomes of non‐hepatic solid organ transplantation in the United States	2
	2
Interpreting shear wave elastography results in chronic hepatitis D virus infection	2
	2
	2
Challenges of hepatitis B treatment in rural Sub‐Saharan Africa: Treatment initiation and outcomes from a public hospital‐based clinic in Kono, Sierra Leone	2
A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia	2